miR-34b在老年鼻咽癌组织中表达及对细胞增殖、侵袭的影响

目的探讨miR-34b在老年鼻咽癌组织中表达及对细胞增殖、侵袭的影响。方法选取初治原发性老年鼻咽癌患者83例,正常鼻咽黏膜组织40例作为对照组,培养人鼻咽癌CNE-2细胞株,根据转染物不同将细胞分为miR-34b转染组、阴性对照组和空白对照组,利用实时荧光定量PCR技术检测老年鼻咽癌及对照组组织中miR-34b表达以及不同转染组细胞中miR-34b表达,MTT比色法检测不同转染组细胞增殖能力,检测细胞黏附能力,Transwell法检测不同转染组细胞侵袭能力。结果老年鼻咽癌组织中miR-34b相对表达量为(0.64±0.09),显著低于对照组的(0.94±0.12),差异有统计学意义(t=14.410,P<0.001);miR-34b在老年鼻咽癌组织中相对表达量与临床分期、T分期、N分期和淋巴结转移有关(P<0.001);miR-34b转染组细胞中miR-34b相对表达量为(0.85±0.10),显著高于阴性对照组和空白对照组,分别为(0.52±0.08)和(0.50±0.07),差异有统计学意义(F=243.329,P<0.001);与阴性对照组和空白对照组相比,miR-34b转染组细胞增殖能力显著降低(P<0.05);miR-34b转染组黏附细胞数显著高于阴性对照组和空白对照组,而侵袭细胞数显著低于阴性对照组和空白对照组(P<0.001)。结论 miR-34b在老年鼻咽癌组织中呈低表达,上调miR-34b表达可减少细胞增殖,增加细胞黏附能力,抑制细胞侵袭能力,有望成为提高鼻咽癌对放射治疗敏感性的目的基因。     

动脉粥样硬化患者血清miR-520b表达水平及相关机制

目的探讨动脉粥样硬化患者血清miR-520b表达水平及相关作用机制。方法选取该院收治的动脉粥样硬化患者42例,收集同期42名健康老年人为对照。qRT-PCR检测外周血清miR-520b表达水平。经targetscan和miRanda数据库预测importin 8(IPO8)为miR-520b的可能靶基因,通过双荧光素酶报告基因检测证实;体外细胞实验采用Western印迹检测miR-520b对人血管内皮细胞IPO8表达的影响;CCK-8法和Tranwells实验检测miR-520b对人血管平滑肌细胞增殖、迁移能力的影响。结果动脉粥样硬化患者血清miR-520b相对表达量低于健康老年人(P<0.05)。双荧光素酶报告基因检测证实IPO8是miR-520b的直接作用靶基因;转染miR-520b类似物人血管内皮细胞IPO8蛋白相对表达量低于类似物阴性对照组(P<0.05);转染特异性miR-520b抑制物后,血管内皮细胞中IPO8蛋白相对表达量高于抑制物对照组(P<0.05)。提升miR-520b表达后人血管平滑肌细胞增殖和迁徙能力均低于相应阴性对照(P<0.05);抑制miR-520b表达后人血管平滑肌细胞增殖和迁徙能力均高于相应阴性对照,差异有统计学意义(P<0.05)。结论动脉粥样硬化患者血清miR-520b表达水平明显降低;miR-520b可通过阻断NF-κB信号通路及抑制血管平滑肌细胞增殖、迁徙来发挥抗动脉粥样硬化的作用。     

核糖核酸干扰沉默生长抑制因子1基因表达对胃腺癌AGS细胞凋亡的影响

目的 探讨RNA干扰沉默生长抑制因子1(ING1)基因表达对胃腺癌AGS细胞凋亡的影响。方法人胃腺癌细胞株AGS经常规培养后分为空白对照组、阴性对照组[转染阴性对照小干扰RNA(siRNA)序列]、siRNA组（转染特异性ING1 siRNA序列）。应用免疫荧光、定量PCR和免疫印迹方法检测转染后不同时间的ING1基因表达沉默效果。应用流式细胞技术检测ING1基因表达沉默对AGS细胞凋亡的影响。结果ING1主要在AGS细胞胞质中表达。在荧光定量PCR技术检测中将空白对照组的ING1基因表达量设为1,则转染后24和40 h阴性对照组的ING1基因相对表达量分别为0.88±0.16和0.92±0.13,siRNA组ING1基因相对表达量分别为0.38±0.09和0.17±0.06。空白对照组和阴性对照组比较,P值分别=0.78和0.82。空白对照组和siRNA组比较,P值均=0.01。阴性对照组和siRNA组比较,P值分别=0.02和0.01。免疫印迹技术检测结果显示,转染后40 h AGS细胞中ING1蛋白表达水平明显下调。空白对照组AGS细胞凋亡率为11.06％±0.97％,阴性对照组、siRNA组转染40 h后AGS细胞凋亡率为11.82％±0.69％和 6.70％±0.41％。空白对照组与siRNA组比较P=0.024。空白对照组与阴性对照组比较P=0.76。阴性对照组与siRNA组比较P=0.019。结论ING1在人胃癌细胞凋亡过程中发挥重要作用,可能成为胃癌基因治疗的新靶点。     

miR-126对人晶状体上皮细胞凋亡的影响

目的探讨miR-126表达水平对人晶状体上皮细胞系HLEB3凋亡的影响及作用机制。方法使用H2O2构建HLEB3体外凋亡模型,qRT-PCR检测miR-126水平变化;使用脂质体2000分别将miR-126模拟物(mimic)和抑制物(inhibitor)以及二者相应的阴性对照转染到HLEB3中,分别上调、下调细胞中miR-126表达,转染48 h后qRT-PCR验证转染效率,流式细胞仪检测各组HLEB3凋亡水平;通过靶基因预测软件预测miR-126可能靶向调控KLF6基因的表达,检测各组HLEB3中KLF6 mRNA和蛋白表达水平。结果 HLEB3凋亡模型中miR-126相对表达量明显高于正常HLEB3,差异有统计学意义(P0.01)。模拟物组HLEB3凋亡率明显低于模拟物阴性对照组;抑制物组HLEB3凋亡率明显高于抑制物阴性对照组;差异均有统计学意义(均P0.05)。模拟物组HLEB3中KLF6 mRNA相对表达量明显低于模拟物阴性对照组,抑制物组KLF6 mRNA相对表达量明显高于抑制物阴性对照组,差异均有统计学意义(均P0.05);模拟物组HLEB3中KLF6蛋白相对表达量明显低于模拟物阴性对照组,抑制物组KLF6蛋白相对表达量明显高于抑制物阴性对照组,差异均有统计学意义(均P0.05)。结论 miR-126在HLEB3凋亡模型中表达上调,miR-126可通过调控KLF6基因表达来影响HLEB3凋亡,在白内障发病机制中发挥作用。     

上调miR-124表达诱导甲状腺癌细胞凋亡的作用及其机制

目的探讨上调微小RNA(miR)-124表达对甲状腺癌细胞凋亡的影响及其作用机制。方法采用实时荧光定量(qRT)-PCR检测正常甲状腺Nthy-ori3-1细胞和甲状腺乳头状癌SW579细胞中miR-124的表达差异;利用脂质体转染Has-miR-124mimics上调miR-124表达,并通过qRT-PCR检测其转染效果;流式细胞仪检测过表达miR-124对SW579细胞凋亡的影响;Western印迹检测过表达miR-124对SW579细胞中磷脂酰肌醇-3-激酶催化亚单位α(PIK3CA)蛋白、蛋白激酶B(AKT)蛋白、磷酸化AKT(p-AKT)蛋白、B细胞淋巴瘤/白血病-2(Bcl-2)蛋白及Bcl-2相关X蛋白(Bax)表达的影响。结果 miR-124在甲状腺癌SW579细胞中的表达明显低于正常甲状腺Nthy-ori3-1细胞(P0.05)。转染Has-miR-124 mimics后,miR-124模拟组细胞中miR-124表达明显高于空白对照组(P0.05),阴性对照组和空白对照组差异无统计学意义(P0.05)。流式细胞仪检测结果显示,与空白对照组相比,miR-124模拟组细胞凋亡率显著升高(P0.05),而阴性对照组与空白对照组差异无统计学意义(P0.05)。Western印迹检测结果显示,与空白对照组相比,miR-124模拟组中PIK3CA、p-AKT和Bcl-2蛋白表达量均显著降低,Bax蛋白表达量显著升高(P0.05),而AKT蛋白的表达量变化不明显(P0.05);阴性对照组和空白对照组PIK3CA、AKT、p-AKT、Bcl-2及Bax蛋白表达量差异均无统计学意义(P0.05)。结论上调miR-124表达可诱导SW579细胞凋亡,其作用机制可能与抑制磷脂酰肌醇3-激酶(PI3K)/AKT信号通路活性,上调Bax蛋白表达和下调Bcl-2蛋白表达有关。     

miR-132在动脉粥样硬化中的表达及对缺氧诱导的血管内皮细胞增殖凋亡的影响

目的探讨miR-132在动脉粥样硬化表达及对缺氧诱导的血管内皮细胞增殖凋亡的影响。方法 RT-PCR检测动脉粥样硬化中miR-132的表达;空转染组、阴性对照组和miR-132抑制剂组转染人脐静脉血管内皮细胞(HUVECs),转染48 h后RT-PCR检测各组细胞中miR-132 mRNA表达;后续实验分为正常培养组、缺氧组、缺氧+miR-132抑制剂组,各组细胞培养48 h后,CCK8及流式细胞仪分别检测细胞的增殖及凋亡情况;Western印迹检测活化的含半胱氨酸的天冬氨酸蛋白水解酶(Cleaved Caspase)3、磷酸化磷脂酰肌醇3-激酶(p-PI3K)、磷酸化蛋白激酶B(p-AKT)蛋白表达。结果 miR-132在动脉硬化组中的表达显著高于对照组(P0.05);转染组miR-132 mRNA表达显著低于空转染组(P0.05);缺氧组和缺氧+miR-132抑制剂组OD_(490)值及PI3K、p-AKT蛋白表达均显著低于正常培养组(P0.05),细胞凋亡率及Cleaved Caspase3蛋白表达显著高于正常培养组(P0.05),缺氧+miR-132抑制剂组OD_(490)值及PI3K、p-AKT蛋白表达显著高于缺氧组,细胞凋亡率及Cleaved Caspase3蛋白表达显著低于缺氧组(P0.05)。结论 miR-132在动脉粥样硬化中高表达,抑制其表达可促进血管内皮细胞增殖及降低细胞的凋亡,其机制与激活PI3K/AKT信号通路有关。     

MiR-21对肺癌细胞增殖与凋亡的影响

目的探讨miR-21对肺癌细胞增殖与凋亡的影响。方法培养人肺癌细胞HBE、H460、A549和H446,将实验分为miR-21 inhibitor组、miRNA scramble组、空白对照组。荧光定量检测肺癌细胞H460、A549和H446 miR-21的表达;荧光定量PCR检测将miR-21 inhibitor和miRNA scramble转染到培养至对数生长期的人肺癌细胞H460后,对照组不转染的各组细胞的表达量;MTT实验检测转染miR-21 inhibitor后对细胞增殖的影响;流式细胞仪检测转染miR-21 inhibitor后对细胞凋亡的影响;Western印迹检测与凋亡相关蛋白的活性。结果肺癌细胞H460、A549和H446miR-21的表达显著高于正常肺癌细胞HBE(P<0.01),由于肺癌细胞株H460的miR-21表达在3个细胞株中高表达,因此选择肺癌细胞株H460做后续研究;将miR-21 inhibitor组和miRNA scramble组转染到肺癌细胞株H460后,荧光定量PCR显示,miR-21 inhibitor组的miR-21的相对表达量为显著低于空白对照组(P<0.01),miRNA scramble组的相对表达量与空白对照组无差异(P>0.05);MTT结果显示,转染4 d后,miRNA scramble组与空白对照组细胞增殖率无差异(P>0.05),而miR-21 inhibitor组显著低于空白对照组(P<0.05),且随时间延长,细胞增殖率逐渐下降;流式结果显示,与空白对照组和miRNA scramble组比较,miR-21 inhibitor组细胞的凋亡率显著升高(P<0.01);Western印迹显示,miR-21 inhibitor组Cleaved-caspase-3和Bax蛋白的表达显著高于miRNA scramble组和空白对照组,而miR-21 inhibitor组Bcl-2蛋白的表达显著低于miRNA Scramble组和空白对照组(P<0.05)。结论下调miR-21的表达,可抑制肺癌细胞H460的生长,增加细胞的凋亡,其作用机制可能与Bcl-2家族的调节有关。     

微小核糖核酸-24对内皮型一氧化氮合酶基因表达的调节及其对血管内皮细胞管腔形成的影响

目的:探讨微小核糖核酸(microRNA)-24(miR-24)对内皮型一氧化氮合酶(eNOS)基因表达调节的分子机制及其对血管内皮细胞增殖、迁移和管腔形成能力的影响。方法:构建miR-24及其反义序列的高表达质粒,分别转染人脐静脉内皮细胞(HUVECs),根据转染质粒将实验细胞分为:miR-24高表达组、miR-24干扰组和空白质粒对照组。用四甲基偶氮唑盐(MTT)检测HUVECs增殖能力,划痕和Transwell试验检测细胞的迁移能力,人工基底膜检测细胞的管腔形成能力;分别用逆转录-聚合酶链反应(RT-PCR)、蛋白免疫印迹法(Western blotting)检测eNOS和Sp1转录因子m RNA和蛋白表达水平。结果:(1)与空白质粒对照组比较,miR-24高表达组细胞增殖能力降低45.45%(0.36±0.04 vs 0.66±0.08,P0.05);miR-24高表达组细胞迁移速度明显减缓,且迁移数目降低74.75%(30.25±3.78 vs 119.80±10.94,P0.01),未能形成明显管腔样结构。(2)与空白质粒对照组比,miR-24高表达组eNOS m RNA降低46.2%(0.49±0.02vs 0.91±0.01,P0.05),蛋白表达减少49.07%(0.55±0.05 vs 1.08±0.05,P0.05);同时Sp1 m RNA降低44.9%(0.49±0.01 vs 0.89±0.02,P0.05),其蛋白质表达量也相应减少54.90%(0.46±0.02 vs 1.02±0.04,P0.05)。在miR-24抑制组中,上述指标较空白质粒对照组降低,但比miR-24高表达组显著升高,特别是小管形成数量、及管腔长度与空白质粒对照组相近。结论:miR-24显著抑制HUVECs的增殖、迁移和管腔形成的能力,并且与miR-24对eNOS的表达调控有关;miR-24明显抑制eNOS表达,Sp1的参与可能是这一调节过程的重要分子机制之一。     

LncRNA NEAT1靶向miR-520b调控口腔鳞癌细胞增殖、凋亡及自噬的分子机制

目的研究长链非编码RNA(LncRNA)核富集的转录物(NEAT)1对人口腔鳞癌细胞Tca8113增殖、凋亡和自噬的影响,并探讨其机制。方法运用qRT-PCR检测人口腔鳞癌细胞Tca8113、人正常口腔上皮细胞HOEC中NEAT1、短链非编码RNA(miR)-520b的表达;将si-NC组(转染si-NC)、si-NEAT1组(转染si-NEAT1)、miR-520b组(转染miR-520b mimics)、miR-NC组(转染miR-NC)、si-NEAT1+anti-miR-NC组(si-NEAT1和anti-miR-NC共转染)、si-NEAT1+anti-miR-520b组(si-NEAT1和anti-miR-520b共转染),用脂质体法转染至Tca8113细胞;MTT法检测各组细胞的增殖;流式细胞术检测各组细胞的凋亡;Western印迹检测各组细胞中LC3Ⅱ/Ⅰ的蛋白表达;双荧光素酶报告基因检测实验检测各组细胞的荧光活性。结果与HOEC相比,Tca8113中NEAT1表达显著升高,miR-520b表达显著降低(P0.05);抑制NEAT1、过表达miR-520b均可抑制Tca8113细胞增殖,促进凋亡和自噬。抑制miR-520b可逆转抑制NEAT1对Tca8113细胞的增殖抑制和凋亡、自噬促进作用。结论抑制NEAT1可抑制口腔鳞癌细胞增殖、促进凋亡和自噬,其机制可能与靶向miR-520b有关,将可为口腔鳞癌的靶向治疗提供依据。     

miR-125b靶向Smad4调控非创伤性股骨头坏死骨髓基质干细胞成骨分化与增殖的相关性

目的探讨miR-125靶向Smad4调控对非创伤性股骨头坏死骨髓基质干细胞成骨分化与增殖的影响。方法培养人骨髓基质干细胞系HMSC-bm,将miR-125b模拟物(mimics)、miR-125b抑制物(inhibitor)和对照(miR-NC)转染到细胞内,qRT-PCR和Western印迹检测过表达对Smad4表达的影响,构建野生型和突变型的Smad4的3'-UTR荧光素酶报告载体,分别命名为Wt-Smad4和Mut-Smad4,将构建好的质粒做三组共转染,即Wt-Smad4与miR-125b mimics、Mut-Smad4和miR-125b mimics以及miR-NC与miR-125b mimics,检测荧光素酶的活性;BMP-2诱导HMSC-bm分化,将miR-125b mimics和si-Smad4转染到分化的细胞内,以不转染的细胞作为参照,检测miR-125b靶向Smad4对细胞分化的影响;将miR-125b mimics、miR-125b inhibitor和miR-NC转染到对数生长期的HMSC-bm细胞系,胆囊收缩素(CCK)8检测过表达对细胞增殖的影响;将miR-125b mimics与pc DNA3.1-Smad4质粒共转染;miR-125b mimics;miR-NC组;miR-NC与pc DNA3.1-Smad4组转染到HMSC-bm细胞系,检测miR-125b靶向Smad4对细胞增殖和分化的影响。结果转染miR-125b mimics组Smad4的相对表达量显著低于miR-125b NC组,转染miR-125b inhibitor组Smad4的相对表达量显著高于miR-125b NC组(P<0.01),Western印迹的检测结果与其一致,荧光素酶结果显示,Wt-Smad4与miR-125b mimics组荧光素酶活性显著低于miR-NC与miR-125b mimics组(P<0.01),结果证实Smad4是miR-125b的靶基因;miR-125b mimics和si-Smad4组Runx2和Osterix mRNA表达量显著低于对照组(P<0.01);CCK8检测结果显示,miR-125b mimics组在24 h、48 h、72 h 3个时间点细胞的增殖率显著高于对照组(P<0.01),miR-125b inhibitor组在3个时间点的细胞增殖率显著低于对照组(P<0.01);miR-125b靶向Smad4对细胞增殖分化的影响试验结果显示,miR-125b mimics组细胞增殖显著高于miR-NC组(P<0.01),miR-125b mimics与pc DNA3.1-Smad4质粒共转染组细胞增殖显著高于miR-NC(P<0.05),miR-NC与pc DNA3.1-Smad4组细胞增殖显著低于miR-NC组(P<0.05),miR-125b mimics组和miR-125b mimics+pc DNA3.1-Smad4组细胞中Runx2和Osterix的mRNA相对表达量显著高于miR-NC组(P<0.01);miR-NC+pc DNA3.1-Smad4组细胞中Runx2和Osterix的mRNA相对表达量显著低于miR-NC组(P<0.01)。结论 Smad4是miR-125b的靶基因,上调miR-125b促进细胞增殖,下调miR-125b减弱细胞增殖,miR-125b靶向Smad4调控HMSC-bm细胞增殖和分化。     

MicroRNA-181b 对衰老内皮细胞血管新生功能的影响

目的研究microRNA-181b（miR-181b）对衰老内皮细胞增殖、迁移和管腔形成等血管新生功能的影响。方法原代培养人脐静脉内皮细胞（Human umbilical vein endothelial cells,HUVECs）,通过传代培养计算细胞群体倍增水平（Population doublings,PDL）,建立HUVECs衰老模型（PDL44）。在PDL44HUVECs中过表达或抑制miR-181b,分刖用MTS法、划痕实验及成管实验检测内皮细胞增殖、迁移和成管功能,结果过表达miR-181b可抑制PDL44内皮细胞的增殖功能18％（P〈O．001）,减少内皮细胞迁移率40％（P=O．032）;反之,给于miR-181b抑制刹可硅著改善PDL44内皮细胞的迁移和增殖：给了血管内皮生长因子（Vascular endothelial growth factor,VEGF）刺激,术观察到miR-181b对PDL44内皮细胞成管功能的调控作用。结论抑制miR＋181b可提高衰老内皮细胞的增殖和迁移能力,提示它可作为一个新的靶点,调节内皮细胞的损伤修复和血管新生。     

miR-206对血管内皮细胞增殖的影响及其机制

目的研究miR-206对血管内皮细胞增殖的影响及其机制,为临床动脉硬化疾病提供新的诊疗方向。方法收集临床病理首次确诊为糖尿病下肢动脉粥样硬化病变的患者病变处动脉内皮组织和正常内皮组织,qPCR检测miR-206的表达;而后通过基础实验研究将HUVEC分为未转染组、miR-206-mimics组和miR-206-inhibitor组,观察转染效率;三组细胞均采用CCK8检测细胞增殖情况,Transwell进行迁移能力评估,流式细胞仪检测细胞周期情况,Western blot检测Cx43表达情况。结果糖尿病动脉硬化患者下肢动脉(均为胫腓动脉)病变处内皮细胞miR-206的mRNA表达较正常组织内皮细胞明显增加(P0.05);HUVEC转染miR-206-mimics后,miR-206表达显著升高(P0.05),转染miR-206-inhibitor后,miR-206表达明显降低(P0.05);在HUVEC转染miR-206-mimics 24 h后,细胞增殖率相比于未转染组和miR-206-inhibitor组要明显降低(P0.05);在HUVEC转染miR-206-mimics后,细胞迁移能力明显降低(P0.05),细胞周期在G2期发生阻滞,而HUVEC转染miR-206-inhibitor后细胞迁移能力提高(P0.05);miR-206-mimics组细胞Cx43表达明显降低,而miR-206-inhibitor组细胞Cx43表达明显增加。结论 miR-206可以抑制血管内皮细胞的增殖,将内皮细胞阻滞在有丝分裂G2期,并且抑制内皮细胞迁移,其对内皮细胞增殖的影响可能是通过调节Cx43表达来实现的。     

miR-181a-5p对人主动脉平滑肌细胞成骨样分化的影响

目的 观察miR-181a-5p对动脉钙化细胞模型的影响,探讨其可能的作用机制.方法 培养人主动脉平滑肌细胞(HASMC),经成骨样分化诱导后使用茜红素染色检测细胞成骨样分化的程度,采用real-time PCR检测成骨样分化标志基因骨钙素(OCN)、Runt相关转录因子2(RUNX2)和碱性磷酸酶(ALP)的mRNA...     

miR-21/PTEN/Akt参与白藜芦醇促EPC的体外成血管能力

目的 探讨miR-21及其下游PTEN/Akt信号通路在白藜芦醇促进大鼠骨髓源性内皮祖细胞(EPC)体外成血管能力中的作用.方法 采用密度梯度离心法分离大鼠四肢骨髓的单个核细胞,培养于含10％胎牛血清的EGM-2MV完全培养基中诱导分化成EPC,实验用3～5代的EPC.白藜芦醇(20 μmol/L)干预12 h后,采用...     

miR-30b对血管平滑肌细胞迁移能力的影响

目的探究microRNA-30b(miR-30b)对大鼠血管平滑肌细胞(VSMC)迁移能力的影响。方法体外分离培养大鼠VSMC,将VSMC随机分为正常对照组(未进行转染)、miR-对照组(转染miR-NC,浓度为50 nmol/L)、miR-30b mimics组(转染miR-30b mimics,浓度为50 nmol/L)。采用实时荧光定量PCR实验检测miR-30b及钙黏附蛋白E-Cadherin的表达情况;采用划痕愈合实验检测VSMC的迁移率;采用Transwell实验检测VSMC的迁移能力;采用Western blot技术检测E-Cadherin蛋白的表达。结果①miR-30b mimics组与正常对照组和miR-对照组比较,miR-30b表达水平升高(P0.05)。②划痕愈合实验结果显示,与正常对照组和miR-对照组相比,miR-30b mimics组VSMC的划痕修复率明显降低(P0.05)。③Transwell实验可见,miR-30b mimics组VSMC的迁移能力较正常对照组和miR-对照组明显减弱(P0.05)。④miR-30b mimics组E-Cadherin mRNA和蛋白的表达较正常对照组和miR-对照组明显增强(P0.05)。结论 miR-30b上调E-Cadherin的表达,从而抑制大鼠VSMC的迁移。     

MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression

Hepatocellular carcinoma (HCC) is a highly vascularized tumor with frequent intrahepatic metastasis. Active angiogenesis and metastasis are responsible for rapid recurrence and poor survival of HCC. We previously found that microRNA-29b (miR-29b) down-regulation was significantly associated with poor recurrence-free survival of HCC patients. Therefore, the role of miR-29b in tumor angiogenesis, invasion, and metastasis was further investigated in this study using in vitro capillary tube formation and transwell assays, in vivo subcutaneous and orthotopic xenograft mouse models, and Matrigel plug assay, and human HCC samples. Both gain- and loss-of-function studies showed that miR-29b dramatically suppressed the ability of HCC cells to promote capillary tube formation of endothelial cells and to invade extracellular matrix gel in vitro. Using mouse models, we revealed that tumors derived from miR-29b-expressed HCC cells displayed significant reduction in microvessel density and in intrahepatic metastatic capacity compared with those from the control group. Subsequent investigations revealed that matrix metalloproteinase-2 (MMP-2) was a direct target of miR-29b. The blocking of MMP-2 by neutralizing antibody or RNA interference phenocopied the antiangiogenesis and antiinvasion effects of miR-29b, whereas introduction of MMP-2 antagonized the function of miR-29b. We further disclosed that miR-29b exerted its antiangiogenesis function, at least partly, by suppressing MMP-2 expression in tumor cells and, in turn, impairing vascular endothelial growth factor receptor 2-signaling in endothelial cells. Consistently, in human HCC tissues and mouse xenograft tumors miR-29b level was inversely correlated with MMP-2 expression, as well as tumor angiogenesis, venous invasion, and metastasis. CONCLUSION: miR-29b deregulation contributes to angiogenesis, invasion, and metastasis of HCC. Restoration of miR-29b represents a promising new strategy in anti-HCC therapy.     

内皮细胞缺氧后miR-210、miR-92a、miR-126表达及意义

目的进一步探讨缺氧后血管新生的调控机制。方法常规方法培养人微血管内皮细胞,低氧培养箱制备内皮细胞缺氧模型（观察组）,正常细胞作为对照组。采用real time PCR法检测两组内皮特异性microRNA（miR-210、miR-92a、miR-126）表达变化。结果与对照组比较,miR-210、miR-92a、miR-126分别上调了（5.19±0.99）、（3.02±0.88）、（3.87±0.83）倍,P均〈0.05。结论缺氧可促使内皮细胞特异性microRNA表达改变,此可能为缺氧后血管新生的主要调控机制。     

Experimental study on the inhibition effect of miR-106a inhibitor on tumor growth of ovarian cancer xenografts mice

Objective:To study the inhibition effect of miR-106 a inhibitor on tumor growth of ovarian cancer xenografts mice.Methods:BALB/c mice were selected as experimental animals,ovarian cancer SKOV-3 cells transfected with miR-106 a inhibitor and its negative control were inoculated subcutaneously,intratumoral injection of miR-106 a inhibitor and its negative control were continued after tumor formation,and they were enrolled as treatment group and model group,respectively.Tumor volume and weight as well as Ki-67 and programmed cell death 4(PDCD4) expression were determined;miR-106 a inhibitor and its negative control as well as miR-106 a mimic and its negative control were transfected into SKOV-3 cells,and expression of PDCD4 in cells was determined.Results:Tumor tissue volume and weight as well as mR NA expression and protein expression of Ki-67 in treatment group were significantly lower than those in the model group while m RNA expression and protein expression of PDCD4 were significantly higher than those in the model group;transfection of mi R-106 a mimic could decrease m RNA expression and protein expression of PDCD4 in SKOV-3 cells,and transfection of miR-106 a inhibitor could increase mR NA expression and protein expression of PDCD4 in SKOV-3 cells.Conclusions:Transfection of mi R-106 a inhibitor can inhibit the growth of tumor in ovarian cancer xenografts mice through increasing the expression of PDCD4.     

Regulatory effects of miR-146a/b on the function of endothelial progenitor cells in acute ischemic stroke in mice

The study aims to explore how microRNA-146a/b (miR-146a/b) regulates the function of endothelial progenitor cells (EPCs) in acute ischemic stroke in mice. Eighty male SPF C57BL/6J mice were evenly divided into the model-6 h, model-12 h, model-24 h (mice suffered from middle cerebral artery occlusion [MCAO] for 6 h, 12 h and model-24 h) and normal groups. EPCs were transfected and assigned into the control, MCAO, MCAO-miR-146a, MCAO-miR-146b and MCAO-miR-146a/b groups. The qRT-PCR was used to detect miR-146a/b expression in EPCs. Expressions of tumor necrosis factor receptor-associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 1 (IRAK1) were detected using western blotting. Cell proliferation and migration of EPCs were testified using CCK-8 assay and scratch test, respectively. Angiogenesis ability of EPCs was observed under microscope. MiR-146a and miR-146b expressions were lower in the model groups than the normal group. There were up-regulated TRAF6 and IRAK1 expressions in the model-6 h, model-12 h and model-24 h groups compared with the normal group. And there were down-regulated TRAF6 and IRAK1 expressions in the MCAO-miR-146a, MCAO-miR-146b and MCAO-miR-146a/b groups than in the MCAO group. Compared with the control group, the proliferation, migration and angiogenesis ability of EPCs were significantly lower in the MCAO group, but higher in the MCAO-miR-146a, MCAO-miR-146b and MCAO-miR-146a/b groups. Besides, the miR-146a/b group showed more enhancement than the MCAO-miR-146a and MCAO-miR-146b groups. MiR-146a/b could down-regulate the TRAF6 and IRAK1 expressions and promote proliferation, migration and angiogenesis ability of EPCs, which was important for recovery of patients with hyperacute ischemic stroke.